VIVUS Company Profile (NASDAQ:VVUS)


VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:VVUS
  • CUSIP: 92855110
  • Web:
  • Market Cap: $84.13 million
  • Outstanding Shares: 105,812,000
Average Prices:
  • 50 Day Moving Avg: $0.94
  • 200 Day Moving Avg: $1.07
  • 52 Week Range: $0.78 - $1.47
  • Trailing P/E Ratio: 2.6639
  • Foreward P/E Ratio: -1.77
  • P/E Growth: -2.7300
Sales & Book Value:
  • Annual Revenue: $133.4 million
  • Price / Sales: 0.63
  • Book Value: $0.05 per share
  • Price / Book: 15.29
  • EBITDA: $67.14 million
  • Net Margins: 24.72%
  • Return on Equity: 3,746.48%
  • Return on Assets: 11.02%
  • Debt-to-Equity Ratio: 40.25%
  • Current Ratio: 5.51%
  • Quick Ratio: 5.20%
  • Average Volume: 799,803 shs.
  • Beta: 0.96
  • Short Ratio: 9.72

Frequently Asked Questions for VIVUS (NASDAQ:VVUS)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.20. The company had revenue of $13.77 million for the quarter, compared to analysts' expectations of $19 million. VIVUS had a return on equity of 3,746.48% and a net margin of 24.72%. The firm's revenue was down 40.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.19) earnings per share. View VIVUS's Earnings History.

When will VIVUS make its next earnings announcement?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for VIVUS.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:

  • David York Norton, Chairman of the Board and Director
  • Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer, Director
  • Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer
  • John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary
  • Guy P. Marsh, Vice President - U.S. Operations, General Manager
  • Johann Noor Mohamed, Vice President, Corporate Controller
  • Wesley W. Day Ph.D., Vice President - Clinical Development
  • Santosh T. Varghese M.D, Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
  • Thomas B. King, Director
  • Herman Rosenman CPA, Director

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VIVUS stock can currently be purchased for approximately $0.80.

MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VIVUS (NASDAQ:VVUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for VIVUS (NASDAQ:VVUS)
Price Target History for VIVUS (NASDAQ:VVUS)
Analysts' Ratings History for VIVUS (NASDAQ:VVUS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for VIVUS (NASDAQ:VVUS)
Earnings by Quarter for VIVUS (NASDAQ:VVUS)
Earnings History by Quarter for VIVUS (NASDAQ VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.13)N/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.3900 EPS
Next Year EPS Consensus Estimate: $-0.4500 EPS


Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for VIVUS (NASDAQ:VVUS)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 35.73%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.29View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.20View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for VIVUS (NASDAQ:VVUS)
Latest Headlines for VIVUS (NASDAQ:VVUS)
DateHeadline logoFinancial Review: VIVUS (VVUS) vs. The Competition - October 17 at 8:26 AM logoVIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review - October 12 at 10:32 PM logoETFs with exposure to VIVUS, Inc. : October 9, 2017 - October 10 at 8:14 AM logoCritical Contrast: VIVUS (VVUS) versus Its Peers - October 9 at 6:28 PM logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 - October 6 at 12:42 PM logoArgos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey - September 29 at 12:34 PM logoOrexigen's (OREX) Contrave Sales Improving on Promotions - September 28 at 10:20 AM logoCritical Survey: VIVUS (VVUS) versus Its Rivals - September 18 at 2:26 AM logoVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest - September 15 at 1:28 AM logoVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH - September 8 at 10:10 AM logoVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis - September 8 at 10:10 AM logoVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension - September 7 at 11:05 AM logoVIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - - September 6 at 10:09 AM logoVIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea - September 6 at 10:09 AM logoVIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound? - September 4 at 3:41 PM logoVIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey - September 2 at 10:24 PM logoVIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share - September 2 at 2:26 AM logoVIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - - August 31 at 1:57 AM logoVIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation - August 30 at 8:54 PM logoVivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha - August 23 at 1:46 PM logoVIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017 - August 23 at 1:46 PM logoCritical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS) - August 19 at 8:44 AM logoVivus Pipeline Review, Analysis and Potential Catalysts - August 10 at 9:34 AM logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq - August 9 at 8:59 AM logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - August 8 at 8:15 AM logoPeregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis - August 5 at 8:36 PM logoVIVUS Reports Second Quarter 2017 Financial Results - August 3 at 4:34 PM logo-$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter - July 27 at 11:17 AM logoVIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on Wednesday - July 26 at 7:48 AM logoVIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation - July 6 at 5:16 PM logoVIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per Share - July 3 at 10:14 AM logoVIVUS (VVUS) Names Thomas King to Board of Directors - - May 26 at 8:31 AM logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - - May 26 at 8:31 AM logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - May 25 at 7:48 AM logoVivus' (VVUS) CEO Seth Fischer on Q1 2017 Results - Earnings Call Transcript - May 3 at 11:55 PM logoVIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference - April 25 at 8:19 AM logoVIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? - Nasdaq - April 10 at 8:24 AM logoVivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi - MarketWatch - March 28 at 8:19 AM logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - March 27 at 7:53 PM logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts - March 27 at 7:53 PM logoVIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi - March 27 at 7:53 PM logo8:32 am Vivus reaches an agreement w/ Sanofi (SNY) for Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and Russia to the co; terms not disclosed - March 27 at 7:53 PM logoVIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta - March 27 at 7:53 PM logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 - March 16 at 6:43 AM logoMid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views - March 10 at 12:21 AM logoEdited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT - March 10 at 12:21 AM logoVivus' (VVUS) CEO Seth Fischer on Q4 2016 Results - Earnings Call Transcript - March 9 at 4:32 AM logoVIVUS INC Files SEC form 10-K, Annual Report - March 9 at 4:32 AM logoVIVUS Reports Fourth Quarter and Full Year 2016 Financial Results - March 9 at 4:32 AM logoVIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 9 at 4:32 AM



VIVUS (VVUS) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.